The global neoantigen cancer vaccine market was valued at USD 24.4 million in 2022, and it will advance at a 67.6% compound annual growth rate, to touch USD 1,322.8 million, by 2030. The key reasons for paying toward the industry advance are the growing research activities and rising cases of cancer throughout the world. Because of the growing importance of … Continua a leggere→